No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
beonemedicines.comNo one on the platform currently holds 6160.HK.
No tracked institution reports a position in 6160.HK as of their last filing.
No one on the platform has traded 6160.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 35.6% | — | — | — | ||
| Rev. Growth % | 40.4% | 76.9% | ||||
| Profit Margin % | 5.4% | -62.6% | -1258.2% | |||
| Free Cash Flow Margin % | 17.6% | -69.5% | -1197.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Also held through funds
2 more books hold 6160.HK indirectly · FLCH 0.7% of fund, VWO 0.2% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.8B | +27.2% | $0.57 | $0.40–$0.78 | — | 13 |
| 2027 | $7.8B | +15.8% | $0.78 | $0.52–$1.07 | — | 13 |
| 2028 | $8.9B | +14.0% | $1.06 | $0.94–$1.17 | — | 8 |
| 2029 | $9.8B | +9.7% | $1.23 | $1.09–$1.35 | — | 10 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $1.00 | $1.24 | +24.0% |
| 2026-05-06 | $0.65 | $1.18 | +82.1% |
| 2026-02-26 | $0.75 | $0.36 | -51.6% |
| 2025-11-06 | $0.54 | $0.65 | +19.9% |
| 2025-08-06 | $0.25 | $0.55 | +118.9% |
| 2025-05-07 | $-0.35 | $0.01 | +102.0% |
| 2025-02-27 | $-0.61 | $-0.86 | -41.1% |
| 2024-11-12 | $-0.67 |
| $-0.69 |
| -3.2% |
| +0.16% |
| $203.9B |
| — |
| 2359.HKWuXi AppTec Co., Ltd. | $194.00 | -1.97% | $561.9B | — |
| 2617.HKTransThera Sciences (Nanjing). Inc. | $9.54 | -0.31% | $3.8B | — |
Source: Financial Modeling Prep · peers by sector/industry